San Francisco Bay Clinical Trial Unit: Expanding COVID-19 Testing in Heavily Impacted Communities in San Francisco

旧金山湾临床试验单位：在旧金山受影响严重的社区扩大 COVID-19 测试

• 批准号: 10166243
• 负责人: Susan Buchbinder
• 金额: $ 60万
• 依托单位: PUBLIC HEALTH FOUNDATION ENTERPRISES
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-06-15 至 2021-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10166243
• 关键词: 2019-nCoV; Area; COVID-19; COVID-19 pandemic; COVID-19 vaccine; Cessation of life; Cities; Clinical Trials Unit; Communities; Diagnosis; Disease; Disease Outbreaks; Epidemic; Event; Healthcare; Human immunodeficiency virus test; Infection; Mission; Neighborhoods; Persons; Populations at Risk; Research; San Francisco; Site; Testing; Therapeutic Intervention; Time; United States; Virus; clinical research site; racial and ethnic disparities; transmission process; treatment trial; vaccine trial

Project Summary/Abstract As of mid-May, 2020, severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19 disease, has been diagnosed in more than 1.3 million persons in the United States and accounted for more than 80,000 US deaths. Identifying persons infected with SARS-CoV-2 before they present to health care can reduce transmission and flatten the epidemic curve. The San Francisco Bay Area was particularly hard hit early in the COVID-19 pandemic in the United States, and like many parts of the United States, has substantial racial/ethnic disparities in the distribution of cases of COVID-19 in the City. The eastern parts of the City have the highest case rates, with most heavily impacted communities including the Mission, Bayview and Sunnydale neighborhoods, and the Tenderloin, but relatively few COVID-19 testing sites exist there. In addition, outbreaks have been occurring in congregate living situations in San Francisco, where testing can be difficult to perform. We plan to increase SARS-CoV-2 testing through 2 low-barrier testing approaches to identify previously undiagnosed persons. First, we will use a mobile testing unit to reach persons in facilities and neighborhoods where COVID-19 rates are high. Second, we will conduct testing through a community mobilization event in a heavily impacted neighborhood in the southeast San Francisco, testing more than 3000 persons over a four-day time period. We will integrate HIV testing into SARS-CoV-2 testing, as rates of HIV testing have dramatically declined since the beginning of the COVID-19 pandemic, and there is substantial overlap in the populations at risk of both types of infection. These activities will have the additional benefit of increasing capacity at the 2 Clinical Research Sites of the San Francisco Bay Clinical Trials Unit to conduct COVID-19 research, including trials of vaccines and therapeutic interventions.

项目总结/文摘